Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid (Q35431110)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

zoledronic acid

1 reference

based on heuristic

inferred from title

Elizabeth Barrett-Connor

6

object named as

Elizabeth Barrett-Connor

0 references

object named as

Jane A Cauley

3

0 references

Kristine Ensrud

5

object named as

Kristine E Ensrud

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

7

object named as

Dennis M Black

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Steven R Cummings

2

object named as

Steven R Cummings

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Douglas C Bauer

4

object named as

Douglas C Bauer

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1

object named as

Trisha F Hue

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

JAMA Internal Medicine

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

174

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

1550-1557

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Exposure to oral bisphosphonates and risk of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Bisphosphonates and breast cancer incidence and recurrence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Breast-cancer adjuvant therapy with zoledronic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Oral bisphosphonate use and breast cancer incidence in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Bisphosphonates induce breast cancer cell death in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Hormonal predictors of bone loss in elderly women: a prospective study. The Study of Osteoporotic Fractures Research Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Confounding and indication for treatment in evaluation of drug treatment for hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Decreased mortality in users of estrogen replacement therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Hormone therapy to prevent disease and prolong life in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

27 July 2018

Use of bisphosphonates and risk of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Factors associated with 5-year risk of hip fracture in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Differential effects of bisphosphonates on breast cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Design of the Fracture Intervention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4398333

26 September 2018

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor characteristics and clinical outcome of elderly women with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Confounding by indication

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrogen replacement therapy after coronary angioplasty in women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrogen replacement therapy and prognosis after first myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect on survival of estrogen replacement therapy after coronary artery bypass grafting

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of bisphosphonates and risk of postmenopausal breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25111880

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1001/JAMAINTERNMED.2014.3634

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35431110&oldid=1984450724"